Pulmonary Research Studies (COPD and Idiopathic Pulmonary Fibrosis)
ASCENT - Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Aclidinium Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD LAS-MD-45
BIPI 1199.177 - Multi-center open-label expanded access program of oral nintedanib 150 mg twice daily in patients with idiopathic pulmonary fibrosis.
PIPF-031 - A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary
Fibrosis Access to Pirfenidone
Call for Info